Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer.

Samuel Martel, Elena Poletto, Arlindo R Ferreira, Matteo Lambertini, Federico Sottotetti, Ilaria Bertolini, Filippo Montemurro, Antonio Bernardo, Emanuela Risi, Elisa Zanardi, Serena Ziliani, Silvia Mura, Chiara Dellepiane, Lucia Del Mastro, Alessandro Marco Minisini, Fabio Puglisi

Research output: Contribution to journalArticlepeer-review


Overweight and obesity are associated with an increased risk of developing many types of cancer, including breast cancer. Moreover, increased body mass index (BMI) seems to be associated with a worse prognosis in patients with HER2-positive early breast cancer. However, little is known about the impact of BMI on the clinical outcomes of HER2-positive metastatic breast cancer (MBC). This was a multicenter retrospective cohort study including 329 consecutive patients with HER2-positive MBC treated with first-line trastuzumab-based regimens. BMI at the time of MBC diagnosis was collected. World Health Organization BMI categories were used: underweight
Original languageUndefined/Unknown
Pages (from-to)142-147
Number of pages6
Publication statusPublished - Feb 1 2018


  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols, therapeutic use
  • Body Mass Index
  • Breast Neoplasms, drug therapy, metabolism, pathology
  • Disease-Free Survival
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Middle Aged
  • Neoplasm Metastasis
  • Proportional Hazards Models
  • Receptor, ErbB-2, metabolism
  • Retrospective Studies
  • Survival Rate
  • Trastuzumab, administration & dosage
  • Treatment Outcome
  • Body mass index
  • HER2-positive
  • Metastatic breast cancer
  • Trastuzumab

Cite this